ArticleEndocrine connections2026
Fibroblast growth factor 21 and its relationship with central precocious puberty in girls.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStudies have shown that obesity and insulin resistance are associated with central precocious puberty (CPP) in girls. Serum fibroblast growth factor 21 (FGF21) levels are associated with obesity and insulin resistance and are also related to ovarian development, reproductive function, and gonadotropin-releasing hormone (GnRH) neuron development. The aim of this study was to investigate the levels of serum FGF21 in girls with CPP.
methodsThis study enrolled 106 girls aged 6-10 years who were evaluated at the hospital's Growth and Development Clinic. The cohort comprised 55 girls diagnosed with CPP as the case group and 51 age-matched girls with normal growth and development as the control group. Data including age, age at onset of puberty or menarche, anthropometric measurements, IGF1 levels, bone age (BA), ovarian and uterine development, hormone profiles, β-Klotho levels, and FGF21 levels were collected and statistically analyzed.
resultsBone age advancement, IGF1, β-Klotho, and FGF21 levels showed statistically significant differences between the CPP and control groups. FGF21 and β-Klotho levels were negatively associated with CPP, with areas under the ROC curve of 0.833 and 0.770, respectively. The optimal cut-off values were 156.28 pg/mL and 7,057.18 pg/mL for β-Klotho. In girls with CPP, the FGF21 levels were weakly positively correlated with the β-Klotho levels (r = 0.273).
conclusionCompared with age-matched girls without pubertal initiation, girls diagnosed with CPP had significantly lower serum levels of FGF21 and β-Klotho, suggesting that FGF21 may be involved in the regulation of pubertal onset. However, the underlying molecular mechanisms require further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.